The presence of some biomarkers, such as mutant IDH, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, epidermal growth factor receptor amplification and p53 mutation, have predictive and diagnostic potential in gliomas (42). This evidence concerns the gene MGMT and central nervous system cancer.